Literature DB >> 27699641

Recent trends and future directions for the medical treatment of ulcerative colitis.

Makoto Naganuma1, Shinta Mizuno2, Kosaku Nanki2, Shinya Sugimoto2, Takanori Kanai2.   

Abstract

Recently, several medical treatments for ulcerative colitis (UC) have been developed, including 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) α treatments. Treatment options including calcineurin inhibitors and anti-TNF treatment for refractory UC are discussed in this article. Furthermore, upcoming treatments are introduced, such as golimumab, vedolizumab, AJM300, tofacitinib. Budesonide foamwill be used as one treatment option in patients with distal colitis. Herbal medicine, such as Qing-Dai is also effective for active UC and may be useful for patients who are refractory to anti-TNFα treatments. In the near future, physicians will able to use many different treatments for UC patients. However, we should not forget 5-ASA and corticosteroids as the fundamental treatments for UC patients.

Entities:  

Keywords:  Anti-TNF treatments; Anti-adhesion antibody; Calcineurin inhibitors; The current treatment guideline for UC; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27699641     DOI: 10.1007/s12328-016-0686-z

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  65 in total

1.  Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.

Authors:  Aurelien Amiot; Jean-Charles Grimaud; Laurent Peyrin-Biroulet; Jerome Filippi; Benjamin Pariente; Xavier Roblin; Anthony Buisson; Carmen Stefanescu; Caroline Trang-Poisson; Romain Altwegg; Philippe Marteau; Thibaud Vaysse; Anne Bourrier; Stephane Nancey; David Laharie; Matthieu Allez; Guillaume Savoye; Jacques Moreau; Charlotte Gagniere; Lucine Vuitton; Stephanie Viennot; Alexandre Aubourg; Anne-Laure Pelletier; Guillaume Bouguen; Vered Abitbol; Yoram Bouhnik
Journal:  Clin Gastroenterol Hepatol       Date:  2016-02-22       Impact factor: 11.382

Review 2.  The aryl hydrocarbon receptor: multitasking in the immune system.

Authors:  Brigitta Stockinger; Paola Di Meglio; Manolis Gialitakis; João H Duarte
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

3.  Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.

Authors:  Haruhiko Ogata; Jun Kato; Fumihito Hirai; Nobuyuki Hida; Toshiyuki Matsui; Takayuki Matsumoto; Katsuyoshi Koyanagi; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2011-09-01       Impact factor: 5.325

4.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

5.  Ciclosporin use in acute ulcerative colitis: a long-term experience.

Authors:  Simon Campbell; Simon Travis; Derek Jewell
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-01       Impact factor: 2.566

6.  The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission.

Authors:  Mari Arai; Makoto Naganuma; Shinya Sugimoto; Hiroki Kiyohara; Keiko Ono; Kiyoto Mori; Keiichiro Saigusa; Kosaku Nanki; Makoto Mutaguchi; Shinta Mizuno; Rieko Bessho; Yoshihiro Nakazato; Naoki Hosoe; Katsuyoshi Matsuoka; Nagamu Inoue; Haruhiko Ogata; Yasushi Iwao; Takanori Kanai
Journal:  J Crohns Colitis       Date:  2016-05-18       Impact factor: 9.071

7.  Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

Authors:  David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann
Journal:  Lancet       Date:  2012-10-10       Impact factor: 79.321

8.  Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis.

Authors:  Hideo Suzuki; Tsuyoshi Kaneko; Yuji Mizokami; Toshiaki Narasaka; Shinji Endo; Hirofumi Matsui; Akinori Yanaka; Aki Hirayama; Ichinosuke Hyodo
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

9.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

10.  Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis.

Authors:  Joris Arts; Geert D'Haens; Miranda Zeegers; Gert Van Assche; Martin Hiele; André D'Hoore; Freddy Penninckx; Severine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-03       Impact factor: 5.325

View more
  8 in total

1.  Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study.

Authors:  Makoto Naganuma; Shinya Sugimoto; Tomohiro Fukuda; Keiichi Mitsuyama; Taku Kobayashi; Naoki Yoshimura; Hidehisa Ohi; Shinji Tanaka; Akira Andoh; Naoki Ohmiya; Keiichiro Saigusa; Takayuki Yamamoto; Yuichi Morohoshi; Hitoshi Ichikawa; Katsuyoshi Matsuoka; Tadakazu Hisamatsu; Kenji Watanabe; Shinta Mizuno; Takayuki Abe; Yasuo Suzuki; Takanori Kanai
Journal:  J Gastroenterol       Date:  2019-09-16       Impact factor: 7.527

2.  Integrating Pharmacology and Microbial Network Analysis with Experimental Validation to Reveal the Mechanism of Composite Sophora Colon-Soluble Capsule against Ulcerative Colitis.

Authors:  Yuxuan Ding; Mingjun Chen; Qiying Wang; Lu Gao; Yang Feng; Shida Wang; Zitian Song; Zhanqi Tong
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-20       Impact factor: 2.629

Review 3.  Efficacy and Safety of Sophora flavescens (Kushen) Based Traditional Chinese Medicine in the Treatment of Ulcerative Colitis: Clinical Evidence and Potential Mechanisms.

Authors:  Mingjun Chen; Yuxuan Ding; Zhanqi Tong
Journal:  Front Pharmacol       Date:  2020-12-10       Impact factor: 5.810

4.  Mass Spectrometric Behavior and Molecular Mechanisms of Fermented Deoxyanthocyanidins to Alleviate Ulcerative Colitis Based on Network Pharmacology.

Authors:  Yunpeng Bai; Guangwen Wang; Jinhua Lan; Ping Wu; Guowu Liang; Jinhui Huang; Zheng Wu; Yirong Wang; Chunbo Chen
Journal:  Int J Anal Chem       Date:  2022-03-21       Impact factor: 1.885

5.  Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.

Authors:  Makoto Naganuma; Kenji Watanabe; Satoshi Motoya; Haruhiko Ogata; Toshiyuki Matsui; Yasuo Suzuki; Lyann Ursos; Shigeru Sakamoto; Mitsuhiro Shikamura; Tetsuharu Hori; Jovelle Fernandez; Mamoru Watanabe; Toshifumi Hibi; Takanori Kanai
Journal:  J Gastroenterol Hepatol       Date:  2021-09-07       Impact factor: 4.369

6.  Analysis of the initial dose and reduction rate of corticosteroid for ulcerative colitis in clinical practice.

Authors:  Masataka Masuda; Norimasa Fukata; Yasuki Sano; Shuhei Nishimon; Mamiko Aoi; Takashi Tomiyama; Toshiro Fukui; Mika Omiya; Kazuichi Okazaki; Makoto Naganuma
Journal:  JGH Open       Date:  2022-08-20

Review 7.  Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis.

Authors:  Makoto Naganuma
Journal:  J Gastroenterol       Date:  2020-08-10       Impact factor: 7.527

8.  Root Extract of Lindera aggregata (Sims) Kosterm. Modulates the Th17/Treg Balance to Attenuate DSS-Induced Colitis in Mice by IL-6/STAT3 Signaling Pathway.

Authors:  Huimin Lai; Zhengbiao Yang; Zhaohuan Lou; Feng Li; Feng Xie; Wei Pan; Cong Xu; Lili Zhang; Sheng Zhang; Lijiang Zhang; Mincong Huang
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.